F8 and hemophilia A: This strategy was implemented for Factor VIII, an essential plasma clotting protein, whose deficiency is responsible for hemophilia A. Gene therapies based on AAV utilize a shortened, but fully functional version of FVIII factor, FVIII-SQ.